Sophiris Bio Reports First Quarter Financial Results and Recent Key Operational Highlights
San Diego, California and Vancouver, British Columbia, April 30, 2013 – Sophiris Bio Inc. (Sophiris, TSX: SHS) (the “Company” or “Sophiris”), a urology company developing a clinical-stage, targeted treatment for benign prostatic hyperplasia (BPH or
Correction – Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ
San Diego, California and Vancouver, British Columbia, February 18, 2013 – Sophiris Bio Inc. (Sophiris, TSX: SHS) (“Sophiris” or the “Company”), a biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate),
Sophiris Bio Reports Fourth Quarter and Year-End 2012 Financial Results and Key Operational Highlights
San Diego, California and Vancouver, British Columbia, February 13, 2013 – Sophiris Bio Inc. (Sophiris, TSX: SHS) (the “Company”), a biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced